

December 2, 2002

Mr. Marc-André Charette
Regulatory Affairs Senior Associate
MDS Nordion
447 March Road
Ottawa, ON K2K 1X8
Canada

Dear Mr. Charette:

This letter is in reference to your application dated September 30, 2002, requesting the inactivation of the GammaMed product line (certificates NR-0220-D-121-S, NR-0220-D-122-S, NR-0220-S-123-S, and NR-0220-S-124-S). In order to complete our review, please provide the following additional information:

1. Please provide the total number of products sold and the total number of products still in use in the GammaMed product line.
2. Please provide information regarding the services that MDS Nordion will provide for users of the GammaMed product line or the identification of an entity that will provide services.
3. Please confirm that MDS Nordion will no longer commercially distribute the GammaMed product line.
4. Please confirm that no changes have been made to the GammaMed product line since the last amendment.

We will continue our review upon receipt of this information. If we do not receive a response from you in 30 days, we will consider your request as having been abandoned and void the active control for your request. This action would be without prejudice to the resubmission of another request.

If you have any questions, please contact me at (301) 415-7637, or John Jankovich at 301-415-7904.

Sincerely,
/RA/

Nima Ashkeboussi, Engineering Aide
Materials Safety and Inspection Branch
Division of Industrial and
Medical Nuclear Safety
Office of Nuclear Material Safety
and Safeguards

December 2, 2002

Mr. Marc-André Charette
 Regulatory Affairs Senior Associate
 MDS Nordion
 447 March Road
 Ottawa, ON K2K 1X8
 Canada

Dear Mr. Charette

This letter is in reference to your application dated September 30, 2002, requesting the inactivation of the GammaMed product line (certificates NR-0220-D-121-S, NR-0220-D-122-S, NR-0220-S-123-S, and NR-0220-S-124-S). In order to complete our review, please provide the following additional information:

1. Please provide the total number of products sold and the total number of products still in use in the GammaMed product line.
2. Please provide information regarding the services that MDS Nordion will provide for users of the GammaMed product line or the identification of an entity that will provide services.
3. Please confirm that MDS Nordion will no longer commercially distribute the GammaMed product line.
4. Please confirm that no changes have been made to the GammaMed product line since the last amendment.

We will continue our review upon receipt of this information. If we do not receive a response from you in 30 days, we will consider your request as having been abandoned and void the active control for your request. This action would be without prejudice to the resubmission of another request.

If you have any questions, please contact me at (301) 415-7637, or John Jankovich at 301-415-7904.

Sincerely,
 /RA/

Nima Ashkeboussi, Engineering Aide
 Materials Safety and Inspection Branch
 Division of Industrial and
 Medical Nuclear Safety
 Office of Nuclear Material Safety
 and Safeguards

Distribution: NMSS13
 SSD 03-02

File Name: E:\Filenet\ML030860226.wpd

To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

| | | | | | | | | | |
|--------|--------------|--|------------|--|------------|--|--|--|--|
| OFFICE | MSIB | | MSIB | | MSIB | | | | |
| NAME | NAshkeboussi | | JJankovich | | UBhachu | | | | |
| DATE | 12 / /2002 | | 12 / /2002 | | 12 / /2002 | | | | |

OFFICIAL RECORD COPY